💸 $29.42, +5.49% as of Jul-23-2025, 4:10 PM ET

Can Centene Get Any Cheaper Than This?

Insiders bought at double the current price just six months ago… and we’ve got receipts. 👇

📦 The Insider Box Score

Back in Dec 2024, directors and executives went on a shopping spree around $59–60 per share:

• 🧠 Thomas Greco (Dir): $1.02M @ $59.75

• 📊 Andrew Asher (CFO): $1.0M @ $58.14

• 👩💼 Sarah London (CEO): $250K @ $60.80

• (And others — all above $58/share)

Today? Shares are half that. Bargain-bin Centene, anyone?

Bar chart showing Centene insider buys exceeding $3M around $60/share.

🧠 Institutions Think Math Is Optional

Institutions own more than 100% of the float. That’s not a typo.
It’s Wall Street’s version of:

“We believe in this stock so much… we’ll borrow shares we don’t have.”

• 🧢 Vanguard: 57.5M shares

• 🎩 BlackRock: 45.2M shares

• 💼 FMR, Norges Bank, State Street… they’re all in.

🔍 For Institutional Ownership breakdown, see here. 

🤕 What Happened?

Centene pulled a "hold my stethoscope" moment and withdrew guidance in July 2025. Why?

🚨 Health Marketplace Chaos:

• Expected $1.8B drop in revenue adjustments (blame risk models).

• Medicaid costs rising (behavioral health, home care, pricey drugs).

• Still profitable, still growing, but short-term EPS will take a hit.

📈 But Wait—Q1 and 2024 Were Pretty Good!

• EPS Q1 ‘25: $2.90 (+28% YoY)

• EPS 2024: $7.17

• 2024 Share Buybacks: $3B 🧨

• Membership up in both Marketplace and Medicare PDP

This isn’t a dying business. This is a healthy one on sale.

👉 Want the full picture? Dive into Centene Corp (CNC)'s financials here.

📉 Valuation = LOL

At $29, Centene is trading like it lost its Medicaid card.

This isn’t cheap. This is thrift-store next to a clearance aisle.

🧠 Why the Market Overreacted

• Short-term guidance chaos? Yes.

• Morbidity risks? Absolutely.

• Long-term value? Still strong.

• 2026 premium resets + cost controls = recovery.

🧨 Risks? Yes.

• Premium hikes = customer churn.

• Medicaid cost bloat in states like FL/NY.

• Regulatory headwinds.

• Bears love turning bruises into selloffs.

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

🐂 But… Opportunity? YES.

Insiders bought before. Institutions still hold. Guidance confusion isn’t business collapse.

Centene’s still cash-generative, still dominant in healthcare programs that matter.

Verdict: Buy the Dip, But Bring Tums

Healthcare is messy. But this mess looks like a buffet of future returns.

👀 You were warned

🚨 Disclaimer:

This is not financial advice. It’s just a second opinion — and yes, we’re billing your sense of humor. 🎪💸 

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny